Accelerate to discover
Related topics
Cytek Biosciences hits flow cytometry milestone: 40 color analysis from a single sample
Oct 17, 2019
Cytek Aurora turning aspirations into realizations: 40 Colors, One Tube. Until recently, developing fluorescence-based...
Vascular imaging using a contrast-enhanced microCT approach
Oct 14, 2019
Are you interesting in MicroangioCT? Do you heard about Vascular imaging using a contrast-enhanced microCT approach?...
Change the way you process cells with Curiox Laminar Wash systems
Oct 8, 2019
Laminar Wash technology is for scientists who believe that quantitative flow cytometry is critical to cell therapy,...
Webinar recording - Highly sensitive structural variant detection for medical genetics
Oct 4, 2019
Follow the webinar outlining how a team at Radboud University Medical Center is assessing ultra-long read optical...
Sep 30, 2019
Enjoy an evening to meet with Cytek technical application specialists and technical sales representatives and share...
Sep 27, 2019
VisualSonics AutoLV allow functional and anatomical analysis of the left ventricle in one click using the power of...
Unlimited capabilities of IncuCyte system: discover the latest Cell Cycle assays
Sep 23, 2019
The IncuCyte Cell Cycle Assay combines easy-to-learn automated image acquisition and integrated analysis of 96- or...
The fastest qPCR thermal cycler in the world
Sep 19, 2019
With a thermal ramp rate of up to 10°C per second, the xxpress NGx is the fastest, real-time thermal cycler in the...
Aug 7, 2018
LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.
New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.
Related technologies: Conventional flow cytometry
Get more info
Brand profile
ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
